August 30, 2014 6:19 PM ET

Biotechnology

Company Overview of ProFoldRx, Inc.

Company Overview

ProFoldRx, Inc. provides protein therapeutics for bio-pharmaceutical companies, research institutions, and government agencies. It also helps companies to create protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. In addition, the company offers services in the areas of protein refolding, protein analytical and aggregate characterization, formulation stability and immunogenicity studies, and microbial expression services. ProFoldRx, Inc. was founded in 2003 and is based in Aurora, Colorado.

12635 East Montview Boulevard

Aurora, CO 80045

United States

Founded in 2003

Phone:

303-926-0337

Fax:

303-926-4292

Key Executives for ProFoldRx, Inc.

Chief Executive Officer and President
Vice President of Finance & Accounting
Vice President of Business Strategy & Development and General Manager of European Operations
Chief Intellectual Property Counsel
Vice President of Therapeutic Development
Age: 49
Compensation as of Fiscal Year 2014.

ProFoldRx, Inc. Key Developments

Lonza Group AG and BaroFold, Inc. Announce Technology Evaluation Agreement for PreEMT

Lonza Group AG and BaroFold, Inc. (ProFoldRx, Inc.) announced a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold's PreEMT(TM) high pressure refolding technology for use in biological development refolding processes. Lonza's evaluation will focus on refolding difficult to express microbial products expressed as inclusion bodies. The PreEMT(TM) unit will be installed for evaluation at Lonza's microbial development and manufacturing plant in Visp, Switzerland. The agreement includes an option for Lonza to extend the platform evaluation to cGMP production analysis.

ProFoldRx, Inc. and Boehringer Ingelheim Announce Strategic Agreement on PreEMT High Pressure Protein Refolding Technology

ProFoldRx, Inc. and Boehringer Ingelheim announced that they have entered into a non-exclusive technology and commercial license option agreement. Boehringer Ingelheim will acquire a laboratory-scale reactor of BaroFold's Pressure Enabled Manufacturing Technology (PreEMT(TM)) that can also be qualified for GMP use. The technology will be installed at Boehringer Ingelheim's microbial facility in Vienna, Austria and will be available for development of biopharmaceutical production processes.

ProFoldRx, Inc. Presents at BIO-Europe 2012, Nov-12-2012

ProFoldRx, Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.

Similar Private Companies By Industry

Company Name Region
Flower Genetics LLC United States
Armed, L.L.C. United States
C2 Therapeutics, Inc. United States
Coserics, LLC United States
Bioreclamation Holdings, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ProFoldRx, Inc., please visit www.barofold.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.